[Skip navigation]FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Drug Evaluation and Research
  HHS Logo links to Department of Health and Human Services website

FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER

horizonal rule
CDER Home About CDER Drug Information Regulatory Guidance CDER Calendar Specific Audiences CDER Archives
 
Powered by Google
 

Bupropion hydrochloride (marketed as the antidepressant Wellbutrin) Information

5/2007: The issues described below have been addressed in product labeling.
Please see
http://www.fda.gov/cder/drug/antidepressants/default.htm

FDA ALERT [7/2005] – Suicidal Thoughts or Actions in Children and Adults

Patients with depression or other mental illnesses often think about or attempt suicide.  Closely watch anyone taking antidepressants, especially early in treatment or when the dose is changed.  Patients who become irritable or anxious, or have new or increased thoughts of suicide or other changes in mood or behavior (or their care givers) should contact their healthcare professional right away

Children

Taking antidepressants may increase suicidal thoughts and actions in about 1 out of 50 people 18 years or younger.  Although bupropion is prescribed for children, FDA has not approved bupropion for use in children.

Adults

Several recent scientific publications report the possibility of an increased risk for suicidal behavior in adults who are being treated with antidepressant medications.  Even before these reports became available, FDA began a complete review of all available data to determine whether there is an increased risk of suicidal thinking or behavior in adults being treated with antidepressant medications.  It is expected that this review will take a year or longer to complete.  In the meantime, FDA is highlighting that adults being treated with antidepressant medication, particularly those being treated for depression, should be watched closely for worsening of depression and for increased suicidal thinking or behavior.

This information reflects FDA’s preliminary analysis of data concerning this drug. FDA is considering, but has not reached a final conclusion about, this information. FDA intends to update this sheet when additional information or analyses become available.

Other Information

Report Adverse Events to MedWatch  

Back to Top     Back to Drug Info

PDF requires the free Adobe Acrobat Reader

Date created: May, 2005, updated May 2, 2007

horizonal rule